Close Menu

NEW YORK (360Dx) – Breath diagnostics firm Owlstone Medical today announced GSK will use its Breath Biopsy platform in a clinical development program evaluating the efficacy of a chronic obstructive pulmonary disease drug candidate.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.